Pharmaceuticals & Biotech|Product Engineering|Improve Quality

NateraGenomic data analysis

Researchers spent months scouring medical literature. GenAI now mines insights in minutes, accelerating cancer test development.

Dec 28, 2025|1 month ago

Key results

Elements Per Test
46
Earlier Detection
Up to 9 mos

The company

Cell-free DNA testing and diagnostics for oncology, women’s health, and organ health.

IndustryPharmaceuticals & Biotech
LocationAustin, TX, USA
Employees1K-5K
Founded2004

Result highlights

  • Data extraction increased from 25 to 46 elements
  • Recurrence detected up to 9 months earlier
  • Potential insight time cut from months to minutes

The story

A global leader in cell-free DNA testing processes over 54,000 tests weekly, generating approximately 1.6 petabytes of complex genomic data across two labs.

Data silos and manual workflows consumed valuable resources, forcing researchers to spend months reviewing medical literature for new test development. This operational friction limited the ability to scale complex analysis operations and deliver rapid results to patients.

The organization automated its genomic pipelines using AWS HealthOmics to handle compute and orchestration, allowing scientists to write workflows in Nextflow without managing infrastructure. A parallel generative AI system uses Amazon Textract and Claude 3.5 Sonnet to extract and analyze unstructured clinical text, storing embeddings in Amazon RDS for semantic search. This architecture is unified within Amazon SageMaker to provide secure data discovery and governance across all research teams.

Quotes

Explore similar

Find AI opportunities for your
business context

Understand what's working with 2,275 recent AI case studies across industries. We structure things so you can find high-impact strategies for your exact context.

Graphic placeholder

Industries covered